|
rs886039484
|
|
|
0.020 |
GeneticVariation |
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs886039484
|
|
|
0.020 |
GeneticVariation |
BEFREE |
P21 Ser31Arg and FGFR2 rs2981582 Polymorphisms as Risk Factors for Early Onset of Breast Cancer in Yogyakarta, Indonesia.
|
31759353 |
2019 |
|
rs879253942
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our data suggests that the polymorphisms G388A, C677T, and H63D are not useful in breast cancer diagnosis, but they may be significant additional prognostic markers related to breast cancer survival.
|
21625954 |
2011 |
|
rs879253942
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.
|
15837541 |
2005 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The G allele of the TP53 R72P polymorphism and T allele of the MDM2 SNP309 polymorphism were putative high-risk alleles and exhibited a combined gene-dose-dependent joint effect on breast cancer risk that was more clearly observed in postmenopausal women.
|
21833626 |
2011 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study was undertaken to investigate the association of p53 Arg72Pro, Ins16bp and G13964C polymorphisms and their haplotypes with breast cancer risk in Tunisian women.
|
20233677 |
2010 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
19707196 |
2009 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046).
|
25750340 |
2015 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy.
|
20638924 |
2010 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These observations suggested that neither the Ins16bp or Arg72Pro polymorphisms considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.
|
18640791 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women.
|
24114315 |
2014 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
|
18058229 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele distribution of the R72P missense mutation between ethnically diverse Jewish breast cancer cases and average risk controls showed significant differences: among non-Ashkenazi breast cancer cases, 62.5%, 33.3% and 4.2% were homozygous, heterozygous and homozygous for the Arg72, Arg72Pro and the Pro72 polymorphism, respectively, whereas for controls, the distribution was 22.4%, 65.4% and 12.2%, respectively (P=0.00052), and among Ashkenazi breast cancer cases, allele distribution was 68.5%, 29.6% and 1.9%, whereas for controls, the distribution was 50%, 40% and 10%, respectively (P=0.0125).
|
15756275 |
2005 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results suggest no effect of either R72P allele on breast cancer risk but a significantly reduced survival for 72P homozygous breast cancer patients.
|
16033823 |
2005 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study implies an association of breast cancer risk with the p53 polymorphism Arg72Pro, but not with p73 G4A.
|
14634508 |
2003 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
|
17719241 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We pooled data from four breast cancer cohorts within the Breast Cancer Association Consortium for which both TP53 R72P and MDM2 SNP309 were genotyped and follow-up was available (n = 3,749).
|
20021639 |
2009 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specifically, two polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon 72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the Spanish population.
|
18781154 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our finding suggests that TP53 (Arg72Pro) polymorphism may play a significant role as risk factor for breast cancer in north Indian breast cancer patients.
|
26553387 |
2016 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Arg72Pro and PIN3(16bp duplication) polymorphisms are proposed to have an effective role in structural changes of p53 and have therefore attracted interest as a risk factor for breast cancer in different populations.
|
25854391 |
2015 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The P53 gene codon 72 Arg/Pro and Her2 gene Ile655Val polymorphisms were not associated with the risk of breast cancer in Turkish women.
|
20380571 |
2010 |